Core Viewpoint - Aptose Biosciences Inc. is set to report its financial results for Q4 and the full year of 2023 on March 26, 2024, along with a corporate update [1]. Group 1: Financial Reporting - The financial results will be disclosed after the market closes on March 26, 2024 [1]. - Analysts can participate in a Q&A session by pre-registering for the conference call [3]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The company has a pipeline of small molecule cancer therapeutics aimed at providing single-agent efficacy and enhancing the effectiveness of other anti-cancer therapies without overlapping toxicities [4]. - Two clinical-stage oral kinase inhibitors are under development: tuspetinib (HM43239) for relapsed or refractory acute myeloid leukemia (AML) and luxeptinib (CG-806) for relapsed or refractory hematologic malignancies [4].

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the "Public Offering") of 5,649,122 common shares of the Company (the "Common Shares") and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Com ...

Aptose Biosciences (NASDAQ:APTO) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company’s shares.Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share. That has it expecting gross proceeds of $8.4 million from the stock offering.To go along with this, each share of APTO stock sold in the offering comes with one warrant. These warrants are for the purchase of another share of the company’s stock. The ex ...

Core Viewpoint - Aptose Biosciences Inc. has announced a public offering of approximately 4.9 million common shares at a price of $1.71 per share, aiming to raise about $8.4 million before expenses [1][3] Group 1: Public Offering Details - The public offering consists of 4,912,280 common shares priced at $1.71 each, with warrants included for the same price [1] - Gross proceeds from the public offering are expected to be around $8.4 million, with underwriters having a 30-day option to purchase an additional 736,842 shares and/or warrants [1][3] - The public offering is anticipated to close on or about January 30, 2024, pending customary closing conditions [3] Group 2: Private Placement Details - A concurrent private placement of $4 million with Hanmi Pharmaceutical will occur, with Hanmi acquiring 19.97% of Aptose's outstanding shares post-placement at a price of $1.90 per share, an 11% premium over the public offering price [2] - Hanmi will also receive warrants to purchase common shares at $1.71 per share [2] - The private placement is expected to close on or about January 31, 2024, subject to customary closing conditions [3] Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to support clinical trials for tuspetinib, manufacture clinical supplies, and for working capital and general corporate purposes [3] Group 4: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [7] - The lead product, tuspetinib, is being studied as a treatment for relapsed or refractory acute myeloid leukemia (AML) [7]

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporatio ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Soumit Roy ...

Financial Performance - The net loss for the three months ended June 30, 2023, was $14,129 thousand, compared to a net loss of $10,565 thousand for the same period in 2022, indicating a 34% increase in losses [19]. - The net loss for the six months ended June 30, 2023, was $27.81 million, compared to a net loss of $22.05 million for the same period in 2022, indicating a 26% increase in losses [19]. - Basic and diluted loss per common share for the three months ended June 30, 2023, was $2.27, compared to $1.72 for the same period in 2022, reflecting a 32% increase in loss per share [19]. - The company reported a net loss per share of $4.47 for the six months ended June 30, 2023, compared to $3.59 for the same period in 2022, indicating a worsening loss per share [62]. - The company reported total operating expenses of $14,452 thousand for the three months ended June 30, 2023, which is a 35% increase from $10,673 thousand in the same period of 2022 [19]. Assets and Liabilities - Total assets decreased from $51,027 thousand as of December 31, 2022, to $26,575 thousand as of June 30, 2023, representing a decline of approximately 48% [16]. - Total current assets decreased from $49.52 million as of December 31, 2022, to $25.26 million as of June 30, 2023, a decline of 49% [15]. - Total liabilities decreased slightly from $13,286 thousand as of December 31, 2022, to $12,789 thousand as of June 30, 2023, a reduction of approximately 4% [16]. - Shareholders' equity fell from $37,741 thousand to $13,786 thousand, a decline of about 64% [16]. - Cash and cash equivalents dropped significantly from $36,970 thousand to $8,400 thousand, a decrease of about 77% [15]. Cash Flow and Funding - The company used $13.5 million in operating activities during the three months ended June 30, 2023, compared to $7.0 million in the same period in 2022 [25]. - The company utilized $24.8 million in cash for operating activities during the six months ended June 30, 2023, compared to $16.7 million for the same period in 2022 [25]. - The company plans to raise additional funds to support its operations, but there is no assurance that such funds will be available on acceptable terms [29]. - The company is evaluating strategies to obtain additional funding for future operations due to substantial doubt about its ability to continue as a going concern [36]. - The company has entered into a committed equity facility with Keystone Capital Partners, allowing for the sale of up to $25.0 million of common shares over a 24-month term [58]. Research and Development - Research and development expenses for the three months ended June 30, 2023, were $10,582 thousand, up 44% from $7,341 thousand in the same period of 2022 [19]. - The company has two clinical-stage investigational products for hematological malignancies: tuspetinib and luxeptinib [28]. - The company expects negative cash flow to continue until regulatory approval is received for its products or revenue exceeds expenses [30]. Stock and Equity - The company issued common shares under the 2022 ATM Facility, raising $1.1 million during the three months ended June 30, 2023 [25]. - A reverse stock split at a ratio of 1-for-15 was approved and took effect on June 6, 2023 [33]. - The company granted 215,000 stock options during the six months ended June 30, 2023, with a weighted average exercise price of $9.93 [68]. - The company recorded share-based payment expense of $2,643,000 for the six months ended June 30, 2023, down from $3,293,000 in the same period of 2022, reflecting a 20% decrease [79]. - The company has a maximum of 113,333 common shares available for sale under the Employee Stock Purchase Plan (ESPP) [67]. Accumulated Deficit - As of June 30, 2023, the company reported an accumulated deficit of approximately $492.1 million, up from $464.3 million as of December 31, 2022 [32]. - The company had working capital of approximately $13.3 million as of June 30, 2023, down from $37.2 million as of December 31, 2022 [32]. - Accrued liabilities increased to $8.084 million as of June 30, 2023, compared to $5.657 million on December 31, 2022 [51].

Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler & Co. Li Watsek – Cantor Fitzgerald Joseph Pantginis – H.C. Wainwright Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...